Therapeutic potential of CAR-expressing mesenchymal stem cells in inflammatory and autoimmune diseases
Volarevic · 2025 · International Journal of Molecular Sciences
What this paper found
CAR-engineered mesenchymal stem cells combine the inflammation-homing properties of MSCs with antigen-specific targeting from CAR-T technology. Preclinical efficacy across multiple disease models, scalability and manufacturing remain the barriers to clinical adoption.
Why this is on the map
Extends Ke et al.'s AS-specific cell therapy work to the broader autoimmune landscape.
On the map under these threads
DOI: 10.3390/ijms26167795· opens in a new tab. The full paper is on the publisher’s site, not here.
Related papers on the board
Papers sharing one or more threads with this one.
A disease-associated gene desert directs macrophage inflammation through ETS2
Nature
Identified a single 'switch' gene called ETS2, sitting on chromosome 21, that turns immune cells inflammatory across AS, IBD, and several other related diseases. Because no current drug targets ETS2, this points to a treatment direction beyond what's already available with TNF and IL-17 blockers.
HLA-B27-associated gut microbiota and amino acid perturbations promote ankylosing spondylitis through M1 macrophage activation
Gut Microbes
Shows that HLA-B27, the gene most strongly linked to AS, reshapes which bacteria live in the gut and how the body handles certain amino acids, which in turn activates the inflammatory immune cells driving the disease. Suggests targeting the gut and these metabolic changes could become a real treatment route.
Breaking boundaries in ankylosing spondylitis: how innovative cell therapies reshape immunity
Frontiers in Immunology
Reviews mesenchymal stem cell and CAR-T cell therapy approaches for AS. MSC therapy shifts inflammatory M1 macrophages toward anti-inflammatory M2; CAR-T is still experimental for AS specifically. Current treatments fail to improve long-term prognosis, cell therapy is positioned as the next frontier.
The role of ETS2 in macrophage inflammation
DNA and Cell Biology
Direct follow-up to the 2024 Nature paper. Shows that ETS2 turns on several inflammatory signals at once, TNF, IL-23, IL-1β, and TL1A, the same signals current biologic drugs target one at a time.